Ipsen Group and Tercica entered into cross-licensing agreement in the field of endocrinology. Pursuant to the agreement Ipsen would grant Tercica exclusive rights to sell Somatuline® Autogel® (lanreotide) for treating acromegaly in North America, while Tercica would grant Ipsen exclusive rights to sell Increlex™ (mecasermin/recombinant human insulin-like growth factor-1) for treating short stature associated with severe primary IGF-1 deficiency (IGFD). Ipsen would also acquire all newly issued shares of Tercica for a total cash consideration of €61.8 M (US$77.3 M).